Brazil Bans Key Feed Antibiotics, Sparking Industry Pivot to Therapeutic Use

TEANECK, N.J. – April 27, 2026 – Brazil's government has enacted a significant policy shift that reverberates across the global animal health and agriculture sectors, prohibiting the use of key antimicrobials as growth promoters in livestock. The new regulation, a move that aligns the South American agricultural powerhouse with other major world markets, is compelling companies like Phibro Animal Health Corporation to strategically adapt their products and business models for a new era of stricter oversight.

On April 27, the Brazilian Ministry of Agriculture and Livestock (MAPA) published Ordinance No. 1617, a landmark regulation that bans the importation, manufacture, and use of performance-enhancing feed additives containing the antimicrobials virginiamycin and bacitracin. These substances have long been used to help animals grow faster and more efficiently. The ordinance provides a 180-day transition period for the industry to comply, after which the use of these antimicrobials will be restricted to therapeutic applications under a veterinarian's prescription.

In response, Phibro Animal Health announced it is working cooperatively with MAPA to ensure an orderly transition. The company, a major player in the animal health space, is not fighting the change but pivoting its strategy to align with the new regulatory landscape.

A Global Health Imperative Arrives in Brazil

Brazil’s decision is not an isolated event but the latest and one of the most significant dominos to fall in a global campaign to curb antimicrobial resistance (AMR). The World Health Organization (WHO) has identified AMR as one of the top public health threats of the 21st century, driven in part by the overuse and misuse of antibiotics in both human medicine and animal agriculture. When microbes are exposed to antibiotics but not completely eradicated, they can evolve to resist the drugs, rendering them ineffective for treating infections in both animals and humans.

This new Brazilian ordinance brings the country's policies more in line with those of other major economic blocs. The European Union, a pioneer in this area, banned the use of all antibiotics for growth promotion back in 2006 and implemented even stricter rules in 2022 that prohibit routine preventative use. Similarly, the United States, through the Food and Drug Administration’s Veterinary Feed Directive (VFD) implemented in 2017, and Canada, through its 2018 regulations, have both moved to eliminate growth promotion claims for medically important antibiotics and require veterinary oversight for their use.

Brazil itself has been on this path for several years. In 2020, MAPA prohibited the use of other antimicrobials like tilosin and lincomycin as growth promoters. The inclusion of virginiamycin and bacitracin in the latest ban marks a significant expansion of this policy, targeting substances widely used in the country's massive poultry and cattle industries.

Phibro's Strategic Adaptation

For Phibro Animal Health, the new regulation necessitates a calculated shift away from the growth-promotion market for these products in Brazil. The company stated in a press release that it is already in the final stages of securing new registrations for virginiamycin specifically for therapeutic use in cattle and broiler chickens, with approvals expected during the 180-day transition period. This move is critical, as it allows the product to remain on the market, albeit for a different purpose: treating, controlling, or preventing specific diseases rather than simply enhancing growth.

Furthermore, the company noted that its bacitracin product already carries therapeutic claims in Brazil, smoothing its transition under the new rules. By repositioning its portfolio, Phibro aims to continue serving the Brazilian livestock market while adhering to the heightened regulatory standards.

Despite the scale of the change, Phibro projects a limited financial impact on its fiscal year 2026 results, citing the transition period as a key buffer. The company plans to provide a more detailed financial outlook during its upcoming earnings call scheduled for May 7, 2026. This confidence suggests a well-prepared strategy to navigate the changing regulatory currents.

The Dawn of the Digital Prescription

A key component of Phibro's adaptation strategy is the introduction of a new digital tool, PhibroVet®. With the new ordinance mandating veterinary prescriptions for the use of these antimicrobials, the process of prescribing, tracking, and managing their use becomes more complex for producers and veterinarians. PhibroVet® is designed to address this challenge head-on.

The digital platform will facilitate the creation, transmission, and management of veterinary prescriptions and maintain a comprehensive history. This not only helps ensure compliance with MAPA's new rules but also represents a significant step toward modernizing veterinary practices in Brazil. By digitizing the prescription process, the platform can improve accuracy, enhance data management for both farmers and regulatory bodies, and create a more efficient workflow for veterinarians who will now serve as crucial gatekeepers for antimicrobial use.

This technological solution highlights a broader trend where regulatory pressure is accelerating digital transformation within traditional industries like agriculture. Instead of viewing the new rules as solely a restriction, Phibro is framing it as an opportunity to introduce value-added services that support compliance and operational efficiency.

Ripple Effects Across the Supply Chain

The impact of Ordinance No. 1617 will be felt far beyond animal health companies. Brazilian veterinarians will see their role and responsibilities expand significantly. They will be legally accountable for authorizing the use of these antimicrobials, requiring a valid Veterinarian-Client-Patient-Relationship (VCPR) and careful diagnostic judgment.

For Brazil's vast network of livestock producers, the ban on growth promoters requires a fundamental shift in animal management. Farmers will need to place a greater emphasis on alternative strategies to maintain animal health and productivity. These include enhancing biosecurity measures to prevent disease outbreaks, optimizing nutrition, and utilizing non-antibiotic feed additives such as probiotics, prebiotics, and organic acids. While these changes may involve initial costs and a learning curve, they are also likely to improve the long-term sustainability of their operations.

Ultimately, by aligning with international standards on antimicrobial stewardship, Brazilian producers may find their products gain broader acceptance in export markets that increasingly demand proof of responsible farming practices. This regulatory evolution, while presenting immediate challenges, positions Brazil's powerful agricultural sector for a future where food safety and public health are inextricably linked to sustainable production.